Immunoglobulin subclass-specific ELISAs were developed for human IgG1, IgG2, IgG3, IgG4, IgAtotal, and IgM directed against Coxsackie B (CB) virus types 1, 2, 3, 4, and 5. In all the assays the solid phase was coated with immunoglobulin class/subclass-specific monoclonal antibodies, followed by an incubation with the serum specimens. Incubation with one of the CB viruses, as well as an incubation with biotinylated serotype-specific monoclonal antibodies to the same virus type provided the virus specificity. Finally, there were incubations with peroxidase labeled Extravidin and the substrate-chromogen system. This ELISA method eliminated the competition between the immunoglobulin classes and subclasses. IgG3 and/or IgG1 were seen most frequently of the IgG subclasses, but IgG2 and IgG4 were also present infrequently. The viral specificity of the antibody subclass assays seems to be predominantly at the enterovirus group level, but this remains to be evaluated in a larger study. IgA and IgM were seen almost exclusively in specimens from patients with acute enteroviral infections, except in the assays with the crude CB5 antigen. This indicates the possible suitability of the IgA and IgM assays as diagnostic tests for enteroviral infections. A larger study is necessary to confirm this finding.

Download full-text PDF

Source
http://dx.doi.org/10.1016/0166-0934(92)90030-hDOI Listing

Publication Analysis

Top Keywords

monoclonal antibodies
8
larger study
8
iga igm
8
enteroviral infections
8
immunoglobulin
4
immunoglobulin class
4
class subclass-specific
4
subclass-specific monoclonal
4
monoclonal antibody
4
antibody sandwich
4

Similar Publications

Purpose: Human epidermal growth factor receptor 2 (HER2)-targeted therapies have shown promise in treating -amplified metastatic colorectal cancer (mCRC). Identifying optimal biomarkers for treatment decisions remains challenging. This study explores the potential of artificial intelligence (AI) in predicting treatment responses to trastuzumab plus pertuzumab (TP) in patients with -amplified mCRC from the phase II TRIUMPH trial.

View Article and Find Full Text PDF

Antibody-drug conjugates (ADCs) hold promise to advance targeted therapy of pancreatic ductal adenocarcinoma (PDAC), where the desmoplastic tumor stroma challenges effective treatment. Here, we explored the urokinase plasminogen activator receptor (uPAR) as a candidate ADC target in PDAC, harnessing its massive tumoral and stromal expression in this stroma-dense tumor. We generated a site-specific ADC offering high-affinity, cross-species reactivity, and efficient internalization of the anti-uPAR monoclonal antibody, FL1, carrying a potent anthracycline derivative (PNU-158692).

View Article and Find Full Text PDF

The production of complex multimeric secretory immunoglobulins (SIgA) in Nicotiana benthamiana leaves is challenging, with significant reductions in complete protein assembly and consequently yield, being the most important difficulties. Expanding the physical dimensions of the ER to mimic professional antibody-secreting cells can help to increase yields and promote protein folding and assembly. Here, we expanded the ER in N.

View Article and Find Full Text PDF

Amyloid self-assembly of α-synuclein (αSyn) is linked to the pathogenesis of Parkinson's disease (PD). Type 2 diabetes (T2D) has recently emerged as a risk factor for PD. Cross-interactions between their amyloidogenic proteins may act as molecular links.

View Article and Find Full Text PDF

Purpose: Durvalumab in combination with gemcitabine/cisplatin has shown a favorable benefit-risk profile in the TOPAZ-1 study for advanced biliary tract cancers (BTC). This analysis evaluated the population pharmacokinetics (PopPK) of durvalumab, and exposure-response for efficacy and safety (ERES) of TOPAZ-1.

Methods: The PopPK model for durvalumab was updated using data from 5 previously analysed studies and TOPAZ-1.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!